Neal Shore, MD, FACS, and Brian M. Shuch, MD, introduce themselves and discuss the growing incidence of kidney cancer, the general prognosis, and early signs and symptoms.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.